A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency

Start Date23 Jun 2015

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

EUCTR2011-002750-31-CZ / Not yet recruitingPhase 3

A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency - ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)

Start Date16 Feb 2015

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

NCT02112994 / CompletedPhase 2

A Multi-Center, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency

This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).

Start Date24 Jun 2014

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

100 Clinical Results associated with Sebelipase Alfa

100 Translational Medicine associated with Sebelipase Alfa

100 Patents (Medical) associated with Sebelipase Alfa

Literatures (Medical) associated with Sebelipase Alfa

08 Nov 2024·Cureus Journal of Medical Science

Lysosomal Acid Lipase Deficiency: A Report of Two Cases and a Review of the Literature

Article

Author: Pacurar, Daniela ; Patrascoiu, Marina ; Oprescu, Ioana ; Nedelcu, Calin ; Dijmarescu, Irina

Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive genetic disease arising from mutations in the lipase A, lysosomal acid type (LIPA) gene, characterised by the formation of cholesterol esters and triglyceride storages, primarily in the liver and spleen. By analysing the level of lysosomal acid lipase (LAL), two forms were described in the literature: Wolman disease and cholesteryl-ester storage disease (CESD). Wolman disease usually manifests with rapidly progressive symptoms within the first year of life, while CESD is a latent condition, with significant features appearing later in life. LAL-D usually presents with a non-specific tableau, thus having the possibility of being incorrectly labelled. LAL activity can be demonstrated by LAL dried blood spot (DBS) testing. Since 2015, sebelipase alfa has been authorised for the treatment of LAL-D in the European Union, changing the course of this disease. This article aims to present two clinical cases of CESD and review the current literature on LAL-D. We presented two cases of CESD who were evaluated in our department for chronically elevated transaminases, one with and one without dyslipidaemia. For both patients, other causes of chronic hepatitis were excluded (viral infections, autoimmune diseases, and metabolic diseases), and LAL DBS testing was positive, establishing the diagnosis of CESD. One of them also underwent genetic testing, and a homozygous mutation of the LIPA gene was identified. LAL-D is a difficult diagnosis to establish, considering the scarcity of knowledge. In addition, neither the LAL DBS test nor LIPA gene sequencing investigations are largely available. Thus, most asymptomatic or minimally symptomatic patients might remain undiagnosed, and multiple complications without clear aetiology might arise, making this disease even harder to diagnose and manage. Nevertheless, even though the introduction of enzyme replacement therapy has improved outcomes for many patients, there still remains a need for increased awareness and understanding of this rare condition among health professionals.

01 Apr 2024·Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

A 14‐step desensitization protocol for sebelipase alfa hypersensitivity in a patient with Wolman disease and secondary hemophagocytic lymphohistiocytosis

Article

Author: Nguyen, Minh H N ; Hajirawala, Monica ; Kim, Alexander Y ; Lyons, Shannon ; Denhardt, Brenna ; Moore, Jenna ; Abel, Trent ; Bruening, Rachel ; Sriaroon, Panida

01 Dec 2022·Genome medicine

Rapid whole genome sequencing of critically ill pediatric patients from genetically underrepresented populations

Letter

Author: Alsheikh-Ali, Alawi ; Al Awadhi, Mohamed ; Taylor, Alan ; Bitzan, Martin ; Yavuz, Lemis ; Abuhammour, Walid ; Al Khayat, Abdulla ; Alfalasi, Roudha ; El Naofal, Maha ; Al Maazmi, Munira Mahmoud ; Ramaswamy, Sathishkumar ; Jadhav, Devendrasing ; Janjua, Dalwinder ; Jain, Ruchi ; Abulhoul, Hamda ; Shankar, Shiva ; Shenbagam, Shruti ; Halabi, Nour ; Abou Tayoun, Ahmad N ; Yaslam, Sawsan

Abstract:

We describe a case series of five infants (age range: 1–90 days; 4 females and 1 male) who presented to Al Jalila Children’s intensive care units (ICU) with complex multisystem disorders. Patients were Emirati, Kenyan, Jordanian, Filipino, or Pakistani. Trio rapid whole genome sequencing (rWGS) was performed on all five patients and their parents within the hospital’s genomics facility. Results were returned within ~37 h from blood sample draws and were diagnostic in 3 out of 5 patients. Positive findings were a homozygous pathogenic variant in POMT1 gene causing muscular dystrophydystroglycanopathy, a mosaic tetrasomy of the short arm of chromosome 12 (12p13.33p11.1) causing Pallister-Killian syndrome, and compound heterozygous pathogenic variants in the LIPA gene causing lysosomal acid lipase deficiency and Wolman disease. The rWGS analysis provided fast and precise diagnostic findings in those 3 patients and also aided in devising better management plans for them in the intensive care setting. For example, the 3-month-old infant with pathogenic variants in the LIPA gene is now a candidate for an FDA-approved, potentially lifesaving enzyme replacement therapy (sebelipase alfa). Our case series emphasize the feasibility and utility of rWGS in pediatric intensive care setting, in a diverse population that has long been underserved in genomic services. Significant investments in local healthcare infrastructure are needed, globally, for more equitable access of genomic medicine among vulnerable patients.

News (Medical) associated with Sebelipase Alfa

29 Feb 2024

·www.pharmaceutical-technology.com

NHS expedites availability of Belumosudil for chronic GVHD

The once-daily tablet hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Credit: fizkes / Shutterstock.com. The National Health Service (NHS) in the UK has expedited the availability of the new drug, Belumosudil (Rezurock), for cancer patients with chronic graft versus host disease (GVHD). The decision provides a treatment that can be administered in the at-home setting, reducing hospital visits. Administered as a once-daily tablet, Belumosudil hinders proteins that trigger the severe inflammatory response linked to chronic GVHD. Clinical trials have demonstrated that up to three-quarters of the subjects responded to the therapy, with significant effectiveness in treating symptoms affecting the mouth, intestine or joints. The treatment is accessible through the NHS England’s Innovative Medicines Fund, which fast-tracks the delivery of the most promising non-cancer drugs to patients. See Also: AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront DNTH-103 by Dianthus Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval Chronic GVHD is a rare but serious condition that can occur after a life-saving stem cell transplant. White blood cells in the donated tissue attack the patient’s organs and weaken their immune system. Approximately one-third of patients who receive stem cell or bone marrow transplants for blood cancers such as leukaemia and lymphoma can develop chronic GVHD. Around 1,200 patients in England undergo such transplants each year. Around 400 go on to develop the condition, which is sometimes mild but for one in ten cases is fatal. For half of patients with chronic GVHD, existing therapies such as pentostatin, rituximab and imatinib are ineffective. Belumosudil will now be made available for 200 severely affected patients who have not responded to two previous therapies. This development comes after the NHS decided to fast-track the funding for the drug based on clinical guidance from the UK National Institute of Health and Care Excellence ( Nice ). Belumosudil is the fourth therapy offered to patients through the Innovative Medicines Fund. In September 2023, the NHS used the fund to roll out Sebelipase alfa, a therapy for treating Wolman’s disease, a rare genetic ailment. NHS England specialised services medical director James Palmer stated: “This rollout is a real breakthrough for patients with graft versus host disease and it will help people living with this debilitating condition effectively manage their symptoms and enhance their quality of life and daily functioning. “It’s great news that the NHS has been able to fast-track funding for a treatment which will have a significant impact for hundreds of patients over the coming years.”

Clinical Result

02 Oct 2023

·www.prnewswire.com

Global Enzyme Replacement Therapy (ERT) Markets, 2017-2022, 2022-2027F, 2032F: Lamzede's FDA Approval Paves the Way for a Brighter Future in Enzyme Replacement Therapies

DUBLIN, Oct. 2, 2023 /PRNewswire/ -- The "Enzyme Replacement Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global enzyme replacement therapy market is expected to grow from $10.03 billion in 2022 to $10.85 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The market is expected to reach $14.79 billion in 2027 at a CAGR of 8.1%. In the forefront of medical advancement, the enzyme replacement therapy (ERT) market stands tall, offering vital treatment avenues for individuals grappling with chronic disorders arising from enzyme deficiencies. The research report delves deep into the nuances of the ERT sector, highlighting market statistics, regional shares, and key players commanding significant market share. ERT's pivotal role in normalizing urinary GAG levels and promoting liver and spleen health is becoming increasingly recognized. Primary enzymes like agalsidase alfa - a critical tool in the combat against Fabry's disease - are reshaping the therapeutic landscape. Our comprehensive report also categorizes other prominent enzymes used, shedding light on their applications in conditions such as Gaucher disease, Pompe disease, and more. A spotlight trend in the ERT realm is the surge in product approvals. For instance, the recent FDA nod to Lamzede (velmanase alfa) in February 2023 marked a significant milestone. As the inaugural enzyme replacement therapy greenlit in the U.S for tackling the non-central neurological manifestations of alpha-mannosidosis, Lamzede offers a promising beacon of hope. Moreover, with the escalating prevalence of rare, chronic, and genetic disorders, the ERT market trajectory looks set for robust growth. The U.S National Library of Medicine projects a near-doubling of individuals aged 50 and above with a chronic ailment by 2050, further emphasizing the critical need for effective enzyme replacement therapies. The report also touches upon the market revenues, detailing contributions from key treatments like Sebelipase alfa, Elosulfase alfa, and more. Our exhaustive coverage ensures businesses and stakeholders are well-armed with insights to navigate the dynamic ERT ecosystem. In a geographical context, while North America reigned supreme in the ERT domain in 2022, the forecasted period paints a promising picture for the Asia-Pacific region. Our study covers a broad spectrum of nations from Australia to the USA, offering a global perspective on this burgeoning market. Harness the power of data-driven insights, industry trends, and strategic opportunities with our comprehensive report, and be poised at the cusp of ERT innovations and advancements. Major players in the enzyme replacement therapy market are Biomarin Pharmaceutical Inc. Leadiant Biosciences Inc. Pfizer Inc. Sanofi S.A. AbbVie Inc. Takeda Pharmaceutical Company Limited Protalix BioTherapeutics Inc. Amicus Therapeutics Inc. Johnson & Johnson Services Inc. Digestive Care Inc. Nestle Health Science Alexion Pharmaceuticals Inc. Allergan Plc. Actelion Pharmaceuticals Ltd. CANbridge Life Sciences Ltd. Chiesi Farmaceutici S.P.A. Astrazeneca Plc. Genzyme Corporation JCR Pharmaceutical Co. Ltd. TEIJIN LIMITED Horizon Therapeutics Plc. Perseo Pharma AG SmartPharm Therapeutics Inc. Key Topics Covered: 1. Executive Summary 2. Enzyme Replacement Therapy Market Characteristics 3. Enzyme Replacement Therapy Market Trends And Strategies 4. Enzyme Replacement Therapy Market - Macro Economic Scenario 4.1. COVID-19 Impact On Enzyme Replacement Therapy Market 4.2. Ukraine-Russia War Impact On Enzyme Replacement Therapy Market 4.3. Impact Of High Inflation On Enzyme Replacement Therapy Market 5. Enzyme Replacement Therapy Market Size And Growth 5.1. Global Enzyme Replacement Therapy Historic Market, 2017-2022, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Enzyme Replacement Therapy Forecast Market, 2022-2027F, 2032F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Enzyme Replacement Therapy Market Segmentation 6.1. Global Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Agalsidase Alfa Agalsidase Beta Galsulfase Other Enzyme Types 6.2. Global Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Gaucher Disease Pompe Disease Fabry Disease Other Applications 6.3. Global Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Oral Parenteral 6.4. Global Enzyme Replacement Therapy Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Hospitals Infusion Centers Other End-Users 7. Enzyme Replacement Therapy Market Regional And Country Analysis 7.1. Global Enzyme Replacement Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion 7.2. Global Enzyme Replacement Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

25 May 2021

·www.biospace.com

UK Says 'Not So Fast' on AstraZeneca's $39 Billion Alexion Acquisition

Leon Neal/Getty Images AstraZeneca’s $39 billion acquisition of Alexion is now being investigated by the UK’s Competition and Markets Authority (CMA), to determine if the deal is anti-competitive. On March 17, 2021, it was reported that the U.S. Federal Trade Commission (FTC) organized a multinational working group to evaluate pharmaceutical mergers. Along with the FTC, the group included the CMA, the Canadian Competition Bureau, the European Commission Directorate General for Competition, the U.S. Department of Justice Antitrust Division, and Offices of State Attorneys General. The commission’s goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.” At that time, the FTC was reviewing the AstraZeneca-Alexion deal. Alexion had filed with the U.S. Securities and Exchange Commission (SEC) at the time, indicating it planned to withdraw and re notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, “in order to give the FTC additional time to review the proposed transaction.” The deal has since received the greenlight from the U.S., Canada, Brazil and Russia, but decisions are still pending from the UK, the EU and Japan. The deal was announced in December 2020. AstraZeneca wanted to bolster its immunology presence. Two weeks ago, Alexion shareholders approved the deal. “We’re very pleased with today’s affirmative shareholder vote, which brings us one step closer to completing a transaction that will accelerate the combined company’s ability to develop and provide access to life-changing medicines for patients with rare and devastating diseases around the world,” said Ludwig Hantson, Alexion’s chief executive officer, at the time. Under the terms of the deal, Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADS), with each ADS worth half of an ordinary AstraZeneca share. That comes to about $175 per share. AstraZeneca’s market presence has typically been on oncology, cardiovascular, renal and metabolism and respiratory diseases. It increased its immunology R&D efforts in immune-mediated diseases. Alexion’s focus is on complement inhibition, a part of the human immune system. Its branded products focus on immune-mediated rare diseases caused by abnormal activation of the complement system. These include Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. Soliris is approved in several countries for paroxysmal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. The company’s Ultomiris (ravulizumab) is a second-generation C5 monoclonal antibody. Other products include Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). If the merger is finalized, the two companies will work to advance Alexion’s pipeline of 11 molecules across more than 20 clinical programs, many in rare diseases. Alexion’s immunology expertise is expected to support AstraZeneca’s presence in immunology and rare diseases. At the time of the announcement, Pascal Soriot, AstraZeneca’s chief executive officer, said, “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.”

AntibodyFirst in ClassAcquisition

100 Deals associated with Sebelipase Alfa

External Link

KEGG	Wiki	ATC	Drug Bank
D10377	Sebelipase Alfa	A16AB14	DB11563

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cholesterol Ester Storage Disease	GB	AstraZeneca PLC	31 Jan 2016
Wolman Disease	EU	Alexion Europe SAS	28 Aug 2015
Wolman Disease	IS	Alexion Europe SAS	28 Aug 2015
Wolman Disease	LI	Alexion Europe SAS	28 Aug 2015
Wolman Disease	NO	Alexion Europe SAS	28 Aug 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Failure to Thrive	Phase 3	US	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	EG	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	FR	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	IE	Alexion Pharmaceuticals, Inc.	04 May 2011
Failure to Thrive	Phase 3	GB	Alexion Pharmaceuticals, Inc.	04 May 2011
Gilbert Disease	Phase 2	US	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	CA	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	CZ	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	FR	Alexion Pharmaceuticals, Inc.	12 Dec 2011
Gilbert Disease	Phase 2	GB	Alexion Pharmaceuticals, Inc.	12 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02112994 (Pubmed \| J Pediatr Gastroenterol Nutr) Manual	Phase 2	Wolman Disease	31	Sebelipase Alfa	myjslfxeqh(nvjgczclhi) = positive 2 pts mpgytcpson (kdmzohbwsj ) View more	Positive	20 Apr 2022
				Sebelipase alfa 3.0 mg/kg qow and 3.0 mg/kg weekly
NCT01757184 (ARISE, Pubmed \| J Hepatol) Manual	Phase 3	Wolman Disease	59	Sebelipase Alfa	bcnassudyh(wieuaubtdh) = zszgeyehfi mdgtbcmiks (sfvwqhzrfd ) View more	Positive	01 Mar 2022
NCT01488097 (LAL-CL04, Pubmed \| Liver Int) Manual	Phase 2	Wolman Disease	8	Sebelipase alfa	taaaonpjrf(qpmllfbonq) = lgdujdalpp nxcdyyoage (miuzxuwois ) View more	Positive	01 Sep 2020
				Sebelipase alfa 3.0 mg/kg	-
NCT02193867 (CTgov)	Phase 2	Wolman Disease	10	Sebelipase Alfa	spkbmpepol(gmbuygnwpr) = uzxdqatbqe xfwjqxvkgn (qyxjkynybe, rburssoyck - xlqvlxvgtq) View more	-	18 Nov 2019
SSIEM2019	Not Applicable	Wolman Disease	19	Sebelipase alfa	djlueaznwl(cedyflqifo) = Of 17 patients tested for ADAs, 10 had detectable titers and 8 developed neutralizing antibodies ukzbmwzuky (dhkzqokjrn ) View more	-	25 Aug 2019
SSIEM2019	Not Applicable	Wolman Disease	-	Sebelipase alfa	sukewxyehb(xedarwpwjy) = eymcnrtfgj sqggjkpdms (jcjevkexfq )	-	25 Aug 2019
LAL-CL06 (EASL2019)	Not Applicable	Wolman Disease	31	Sebelipase alfa 1.0 mg/kg	dfjkjmxeyy(mfwoezjdvi) = yvkgetjmkk bcrxvkbfko (ikniiiqgfw ) View more	Positive	13 Apr 2019
				Sebelipase alfa 3.0 mg/kg	dfjkjmxeyy(mfwoezjdvi) = lzimgqwdsr bcrxvkbfko (ikniiiqgfw ) View more
NCT02112994 (CTgov)	Phase 2	Wolman Disease	31	Sebelipase Alfa	lwsnzkxprp(ojnezzotda) = vxznatrzsk buzacynbqv (srpwbplnng, rkoxzrhagc - ssvuwxacun) View more	-	15 Jan 2019
NCT01307098 (CTgov)	Phase 1/2	Gilbert Disease \| Wolman Disease	9	Sebelipase alfa 0.35 mg/kg (Sebelipase Alfa 0.35 mg/kg)	kfvvgxfbud(dattsxusbz) = seipjtjzwr ieirzomyjv (zcwagnfduc, wqlwenjsqq - koloiwzauc) View more	-	11 Dec 2018
				Sebelipase alfa 1 mg/kg (Sebelipase Alfa 1 mg/kg)	kfvvgxfbud(dattsxusbz) = rnjfyucajp ieirzomyjv (zcwagnfduc, xrvbzhcmrm - ofnusfxtss) View more
NCT01371825 (VITAL, Pubmed \| Orphanet J Rare Dis) Manual	Phase 2/3	Wolman Disease	30	sebelipase Alfa	hqqszxfyeu(gpxpysgetd) = oyabslpapv tslqsmzmsx (gmdpgdcnam, 30 - 93) View more	Positive	08 Feb 2017
				historical control	hqqszxfyeu(gpxpysgetd) = airgvqnvca tslqsmzmsx (gmdpgdcnam, 0 - 16)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis